Lupin has received United States Food and Drugs Administration (UFDA)’s approval for Gatifloxacin 0.5% ophthalmic solution. Gatifloxacin, a broad-spectrum antibiotic, is formulated as eye drops for ophthalmic use. It is indicated for the treatment of bacterial conjunctivitis and keratitis (including corneal ulcer) and is a fluoroquinoline antibacterial antibiotic that acts by inhibiting bacterial topoisomerases II and IV, enzymes which are essential for bacterial DNA replication, transcription and translation. Earlier, in July the company received FDA tentative approval for Gatifloxacin ophthalmic solution.
Recently, Lupin’s - US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Rifampin Capsules USP, 150 mg and 300 mg strengths from the United States Food and Drugs Administration (USFDA).
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
